Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026)

Ani Pharmaceuticals has disclosed Income from Continuing Operations across 16 years of filings, most recently posting 29492000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 29492000.0, up 88.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 92124000.0 (up 537.89% YoY), and the FY2025 annual result was 78337000.0, up 522.94% from the prior year.
• Income from Continuing Operations came in at 29492000.0 for Q1 2026 at Ani Pharmaceuticals, up from 27490000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 29492000.0 in Q1 2026 to a low of 24166000.0 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 1439000.0 (2023), against an average of 3538294.12.
• Across the five-year window, Income from Continuing Operations slumped 23506.98% in 2022 and soared 1165.25% in 2024, its largest moves.
• Ani Pharmaceuticals' Income from Continuing Operations stood at 4243000.0 in 2022, then surged by 127.2% to 1154000.0 in 2023, then sank by 990.12% to 10272000.0 in 2024, then surged by 367.62% to 27490000.0 in 2025, then grew by 7.28% to 29492000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 29492000.0 (Q1 2026), 27490000.0 (Q4 2025), and 26617000.0 (Q3 2025), per Business Quant data.